Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASCO 2021 Highlights
ASCO 2021 Presidential Address: Eliminating Disparities in Cancer Care
By
Wayne Kuznar
ASCO 2021 Highlights
,
Disparities in Cancer Care
August 2021, Vol 12, No 4
The theme for the American Society of Clinical Oncology (ASCO) 2021 virtual annual meeting was “Equity: Every Patient. Every Day. Everywhere.” As ASCO President Lori J. Pierce, MD, FASTRO, FASCO, explained during her opening address, there is an urgent need to focus on effective ways to eliminate racial and socioeconomic disparities so that every patient can receive care that results in the best possible outcome.
Read Article
Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC
By
Phoebe Starr
ASCO 2021 Highlights
,
Lung Cancer
August 2021, Vol 12, No 4
Treatment with the immune checkpoint inhibitor atezolizumab (Tecentriq) following surgical resection and chemotherapy significantly improved disease-free survival (DFS) compared with best supportive care (BSC) alone in patients with stage II-IIIA non–small-cell lung cancer (NSCLC) and tumor composite score PD-L1 ≥1%, according to interim results from the phase 3 IMpower010 clinical trial, which were presented at the ASCO 2021 virtual annual meeting.
Read Article
Rapid Biosimilar Adoption Possible in Community Oncology Practice
By
Chase Doyle
ASCO 2021 Highlights
,
Biosimilars
August 2021, Vol 12, No 4
Biosimilars have the potential to create a more sustainable healthcare environment by offering substantial cost-savings and expanding patient access to lifesaving therapies. At the ASCO 2021 virtual annual meeting, Lalan S. Wilfong, MD, Executive Vice President, Value-Based Care and Quality Programs, and Medical Oncologist/Hematologist, Texas Oncology, Presbyterian Cancer Center Dallas, TX, discussed how a community practice model for therapeutic interchange of brand drugs to biosimilars led to a significant increase in utilization of biosimilars and substantial cost-savings over the course of a single year at his institution.
Read Article
Novel LAG-3–Blocking Antibody plus Nivolumab Shows Promise as First-Line Treatment in Advanced Melanoma
By
Wayne Kuznar
ASCO 2021 Highlights
,
Melanoma
August 2021, Vol 12, No 4
The addition of the lymphocyte activation gene-3 (
LAG-3
)–blocking antibody relatlimab to nivolumab (Opdivo) led to significantly longer progression-free survival (PFS) compared with nivolumab alone in previously untreated patients with advanced melanoma, according to results of the phase 3 RELATIVITY-047 clinical trial presented at the ASCO 2021 virtual annual meeting.
Read Article
¹⁷⁷Lu-PSMA-617 Prolongs Survival in Patients with Metastatic Castration-Resistant Prostate Cancer
By
Phoebe Starr
ASCO 2021 Highlights
,
Prostate Cancer
August 2021, Vol 12, No 4
The addition of
177
Lu-PSMA-617, a radionuclide therapy that targets prostate-specific membrane antigen (PSMA), to standard-of-care treatment resulted in a 38% reduction in the risk for death versus standard of care alone in men with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase 3 VISION clinical trial, which were presented during a plenary session at the ASCO 2021 virtual annual meeting.
Read Article
Early Phase 3 Results Show Survival Benefit with Nivolumab-Based Regimens in Advanced Esophageal Squamous-Cell Cancer
By
Wayne Kuznar
Gastrointestinal Cancers
,
ASCO 2021 Highlights
August 2021, Vol 12, No 4
Early results from the CheckMate-648 clinical trial, which evaluated the efficacy and safety of Opdivo (nivolumab), a PD-1 inhibitor, plus Yervoy (ipilimumab), a CTLA-4 inhibitor, or nivolumab plus chemotherapy, suggest a potential new standard of care for the first-line treatment of patients with advanced esophageal squamous-cell carcinoma (ESCC). These findings were presented at the ASCO 2021 virtual annual meeting by Ian Chau, MD, Consultant Medical Oncologist, Gastrointestinal and Haemato-Oncology, Royal Marsden Hospital, Sutton, United Kingdom, and lead investigator of the trial.
Read Article
Enfortumab Vedotin Extends Survival in Metastatic Urothelial Cancer
By
Phoebe Starr
ASCO 2021 Highlights
April 2021, Vol 12, No 2
In patients with metastatic urothelial cancer who received previous therapy, as well as in cisplatin-ineligible patients with this cancer, enfortumab vedotin-ejfv (Padcev) improved overall survival (OS), according to new data presented at the 2021 ASCO Genitourinary Cancers Symposium. The data come from the phase 3 EV-301 study and cohort 2 of the phase 2 EV-201 study. Experts believe this antibody–drug conjugate will become a new standard of care in the treatment of patients with advanced urothelial cancer.
Read Article
Bemarituzumab, FGFR2b Inhibitor, Improves Survival in Advanced Gastric Cancer with FGFR2b Mutation
By
Wayne Kuznar
ASCO 2021 Highlights
April 2021, Vol 12, No 2
Bemarituzumab, an investigational first-in-class humanized immunoglobulin G1 monoclonal antibody that selectively binds to
FGFR2b
, improved progression-free survival (PFS) and overall survival (OS) when added to the modified FOLFOX6 (mFOLFOX6) chemotherapy in patients with
FGFR2b
-positive advanced gastric or gastroesophageal junction (GEJ) cancer in the phase 2 FIGHT randomized clinical trial. The results were presented at the 2021 ASCO Gastrointestinal Cancers Symposium.
Read Article
First CD73 Inhibitor Induces Responses in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
By
Wayne Kuznar
ASCO 2021 Highlights
,
Breast Cancer
April 2021, Vol 12, No 2
A small-molecule CD73 inhibitor (AB680) induced a 41% overall response rate (ORR) when combined with chemotherapy (with nab-paclitaxel and gemcitabine), plus the novel PD-1 inhibitor zimberelimab, as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma, according to results of the dose-escalation portion of a phase 1/1b study known as ARC-8.
Read Article
Zanidatamab Shows Promising Activity in Patients with HER2-Overexpressing Gastric Cancers
By
Wayne Kuznar
ASCO 2021 Highlights
April 2021, Vol 12, No 2
The
HER2
-targeted bispecific investigational antibody zanidatamab, either as monotherapy or in combination with chemotherapy, has shown promising antitumor activity in an ongoing phase 1 study of patients with
HER2
-expressing biliary tract cancer or gastroesophageal adenocarcinoma, reported Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics, M.D. Anderson Cancer Center, Houston, TX, at the 2021 ASCO Gastrointestinal Cancers Symposium.
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma